Janumet XR 100/1000 is a medicine containing the active ingredient(s) sitagliptin + metformin. On this page you will find out more about Janumet XR 100/1000, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: sitagliptin + metformin
Information for medicine and pack size:
Janumet XR 100/1000 modified release tablet, 28
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
JANUMET and JANUMET XR are indicated as initial therapy in patients with type 2 diabetes mellitus to improve glycaemic control when diet and exercise do not provide adequate glycaemic control, when dual sitagliptin and metformin therapy is appropriate (i.e. high initial HbA1c levels and poor prospects of response to monotherapy).,JANUMET and JANUMET XR are indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus inadequately controlled on sitagliptin or metformin alone or in patients already being treated with the combination of sitagliptin and metformin.,JANUMET and JANUMET XR are indicated in combination with a sulfonylurea as an adjunct to diet and exercise in patients with type 2 diabetes mellitus when combination therapy with metformin and sulfonylurea does not provide adequate glycaemic control.,JANUMET and JANUMET XR are indicated as an adjunct to diet and exercise to improve glycaemic control in combination with insulin in patients with type 2 diabetes mellitus inadequately controlled on insulin and metformin, or in patients already being treated with the combination of sitagliptin, metformin and insulin.
Table of characteristics
Blue, bi-convex oval, film coated tablet, debossed "81" on one side and plain on the other.
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Tablet, modified release|
|Route of administration||Oral|
28 tablets: Prescription Only Medicine, or Prescription Animal Remedy
7 tablet starter pack: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||Store in Original Container|
|Life time||2 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 May 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.